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ABSTRACT 
Background: Dengue fever is one of the commonest diseases in tropical countries and carries significant morbidity and 
mortality. Thrombocytopenia (low platelets) is one of the very common manifestations in case of dengue infection. Platelet 
transfusion in dengue always remains controversial. Objective: Present study was conducted to study precise criteria and 
transfusion trigger for platelet transfusion in our set-up. Materials and Methods: This study was conducted on 112 
serologically antibody positive confirmed dengue patients admitted in a Hospital, Powai, Mumbai, between 1st of August to 
30th October 2017. The age groups of the included patients were within 20-50 years and did not have any co morbidity and 
were diagnosed at OPD. Indication for hospitalization includes high grade fever (>101° F) and platelet counts less than 
100,000 along with other viral prodromal symptoms. Clinical data, reports of laboratory investigations, platelets requirements 
and data obtained from daily follow-up and record sheets were analyzed. Results: In the serologically positive confirmed 
cases, the prevalence of thrombocytopenia (count <100,000/mm3) was 97% on admission and there was no bleeding recorded 
in any patient. Out of 112 serologically confirmed dengue cases, only 1 (<1%) patient of dengue received platelet transfusion 
whose platelet counts were <7000/mm3 and he had petechiae all over the body. Total 9 patients had platelet count 
<10000/mm3 (8.03%), 28 (25%) patients had platelet count <20,000/mm3, 52 (46%) had a platelet counts <40,000/mm3 while 
total 79 (70.53%) patients had platelet counts <50,000/mm3. In the study population, 28 (25%) patients had platelet count 
<20,000/mm3 and 9 (8.03%) patients had platelets count <10000/mm3, only 1 patient had petechiae; hence platelet transfusion 
was given. For all other patients who had platelet counts <20,000/mm3, their clinical parameters were monitored strictly and 
frequent manual platelet counts were done. These patients were not given any transfusion. Conclusion: This study suggests 
that bleeding due to thrombocytopenia in case of dengue fever is not a common occurrence especially, in otherwise healthy 
adult or middle aged patients. Those with no or minimum co morbidities and strict monitoring of symptoms are required to 
preserve the resources and to avoid unwanted platelet transfusions. Platelet count should not be a bench mark for someone to 
transfuse the platelet. Signs of bleeding, other co-morbid factors and clinical parameters should be taken in to consideration 
before starting platelet transfusions. 
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engue fever (DF) is one of the commonest 
diseases in tropical countries and carries 
significant morbidity and mortality if goes 
unrecognised or not taken care properly. DF, dengue 
haemorrhagic fever (DHF), and Dengue Shock Syndrome 
(DSS) have emerged as a global public health problem in 
recent decades. The South-East Asian countries such as 
India, Indonesia, Myanmar, and Thailand are at the highest 
risk of DF/DHF accounting for nearly half of the global 
risk due to tropical climates and sanitary habits. 
Thrombocytopenia (low platelets) is one of the commonest 
findings in case of dengue infection. Platelet transfusion in 
D 
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dengue always remains controversial and there are no strict 
guidelines about when to transfuse the platelets, in case of 
dengue with thrombocytopenia. Bleeding in case of DF is 
one of the most severe complications and is associated 
with higher morbidity and mortality in DHF/DSS. 
Bleeding manifestations are highly variable and many of 
the times does not correlate with the laboratory findings  in 
the coagulation profile like platelet counts, activated 
partial thromboplastin time (APTT), prothrombin time 
(PT), international normalized ratio (INR) etc. Factors like 
mild degree of disseminated intravascular coagulation 
(DIC), hepatic dysfunction and low plantlets act 
synergistically to cause bleeding in dengue patient [1]. 
Severe bleeding is related to severe thrombocytopenia [2].  
Platelet transfusion is given only to those patients who 
is either bleeding or having other complications or 
haemorrhagic symptoms due to low platelets. Platelet 
count should not be a bench mark for someone to transfuse 
the platelet counts like always happens but signs of 
bleeding; other co-morbid factors and clinical parameters 
should be taken in to consideration before starting platelet 
transfusion. We have conducted the study with an aim to 
show complications in a patients with lower than 10000 
platelet counts and the need of blood transfusion.  
METHODS 
This prospective observational study was conducted on 
serologically proven dengue patients who were admitted in 
a hospital in Powai, Mumbai, between 1st August 2017 
and 30th September 2017. After getting the informed 
consent and ethical committee approval and as per the laid 
down inclusion criteria, 112 confirmed dengue patient with 
clinical symptoms and fulfilling the case definition criteria 
of DF and DHF of WHO3, were included in this study and 
followed up during their hospital stay. Excluding criteria 
were the dengue patients having age more than 50 years or 
any co-morbidities or platelet counts >100,000/mm3. 
Clinical data were collected through interviewing the 
patients or their attendants/relatives and careful physical 
examination of the patients conducted by the physician. 
Reports of laboratory investigations, dengue antibodies, 
platelet requirements and data obtained from daily follow-
up details, were analyzed. All the patients were admitted 
through OPD who were within 20-50 years of age, having 
high grade fever (>101° F), having Dengue IgM positive 
with platelet counts <100,000/mm3.  
RESULTS 
Of the 112 serologically positive (positive for anti-dengue 
IgM antibodies) in the study, all cases falls in the category 
of DHF if we take the platelet as a criteria for classification 
of dengue here as per the WHO guidelines [3]. The 
involvement of all age groups, especially an adult 
predominance, was observed. All the patients had stable 
vitals except fever and there was no evidence of any 
hemorrhagic shock in any of the patient. The mean age of 
the dengue patient was 27 years and the most belonged to 
the 21-30 year age group, which included 73 patients 
(65.17%). Platelet count of <100,000/mm3 was found in 
112 (100%) patients and haematocrit value of >45% was 
found in 32 patients (28.57%) at the time of admission. 
Hemorrhagic or bleeding manifestations were present in 
only 1 (<1%) patients of dengue infection, which mainly 
included petechiae and small echmyotic patches over the 
lower limbs. Any other bleeding manifestations like 
epistaxis, hematemesis, melena, gum bleeding, etc., were 
not noticed in any of the patients. Only 1 among the 112 
serologically confirmed patients (<1%) received platelet 
transfusion therapy. 
In the serologically confirmed cases, the prevalence of 
thrombocytopenia was 97% on admission and no bleeding 
was recorded in any patient. Out of 112 serologically 
confirmed dengue cases, only 1 patient (1%) of dengue 
received platelet transfusion whose platelet counts were 
<7000/mm3 and he had petechiae all over the body. Total 
9 patients had platelet count <10,000/mm3 (8.03%), 28 
patients (25%) had a platelet count < 20,000/mm3, 52 
(46%) had a platelet counts <40,000/mm3 while total 79 
(70.53 %) patients had platelet counts <50,000/mm3. Out 
of 28 patients with a platelet count <20,000/mm3, and 9 
patients platelets count <10000/mm3, only one patient had 
petechiae; hence, platelet transfusion was given. For all 
other patients who have platelet counts <20,000/mm3, 
their clinical parameters were monitored strictly and 
frequent manual platelet counts were done and no 
transfusion was given to any of these patients. 
All the patients recovered fully and were discharged within 
2-3 days of their admission. The platelet counts had 
increased considerably during their stay in hospital and the 
average platelet counts of the patients at discharge were 
around 75,000/mm3 with persistent rising trends of the 
platelets and stable hemodynamic. Besides platelet 
transfusion, no fresh frozen plasma (FFP) and packed red 
blood cell (PRBC) were transfused to any of the dengue 
patients.  
There was only one patient who was suffering from vivax 
malaria along with dengue fever.  No patients died during 
hospitalization (mortality rate 0%). No patient had any 
clinical manifestations like septicaemia, or multi-organ 
failure in other studies. Another finding in our study is that 
we treated all patients with only antacids, antiemetic, IVF, 
multivitamins and paracetamol. No patient in this study 
received any of the antibiotics. Only one patient who had 
vivax malaria was given anti malarial but no antibiotics. 
There are studies where many people have given 
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antibiotics and shown some benefit while our study clearly 
shows that no antibiotics are required in cases of dengue 
management and it does not change the outcome of the 
patients. 
DISCUSSION 
Dengue fever is a major public health problem in many of 
the tropical countries like India. Mumbai is one of the big 
cities in India where, dengue is endemic. This study 
showed that the majority of dengue cases were adult with 
the largest proportion in the age group of 21-30 years. This 
is in accordance with the findings of Pervin et al [4]. 
Thrombocytopenia was found in 100% of the confirmed 
cases on admission; this prevalence is comparable with the 
findings of Chairulfatah et al. who found a similar 
incidence of 83% in hospitalized dengue patients [2]. 
Unlike other findings reported Shivbalan et al. and 
Chairulfatah et al. in which, significant bleeding in patients 
with thrombocyte count <15,000 - 20000/mm3, in our 
study there is no significant bleeding in any of the patients 
with platelet counts even <10000/mm3 [1,2].  
Published data from various institutions [5-7] and 
country have put varying figures as the trigger for platelet 
transfusion in hospitalized dengue patients. The DHS 
guidelines stipulate that platelet transfusion should be 
given to patients with platelet count < 20,000/mm3. In our 
study, only 1 patient received platelet transfusion which is 
unlike other earlier studies. Many times the prescription 
for blood components are not based on medical rationale, 
but as a response to an intense social pressure on the 
treating physicians by the patients and their relatives. 
Many of the times, there are inappropriate platelet 
transfusions even if the patients’ platelet count is 
>20,000/mm3 [8]. 
Some studies have tried to make the appropriate 
guidelines to trigger for blood or platelet transfusion in 
case of DF where again, platelet transfusion is advised if 
the platelet is less than 10000 even if there is no sign of 
bleeding [9- 11] A restrictive strategy for platelet 
transfusion based on clinical features and low platelet 
count thresholds proved to be feasible and safe for adult 
dengue patients [10]. As per the WHO guidelines, patient 
who are having counts <10,000/mm3, comes under the 
category of high risk and frequent monitoring of the 
platelets apart from close monitoring of the vital signs are 
mandatory [3]. While many other people had stressed on 
the role of platelet transfusion even if the platelet counts 
are more then 10- 20000/mm3 just to be on safer side 
[8,9,11]. 
Our study aim was to tell all the clinician is that 
platelet count is not the trigger for blood transfusion so we 
should stop counting the numbers to decide about the 
platelet transfusion. Similar to our study another study was 
published from Bangladesh also showed similar outcomes 
where, only one patient with platelet counts <10,000/mm3 
has undergone blood transfusion [12]. As per WHO 
criteria, all dengue patients can be categorized as per the 
risk, into the high, moderate, low and no risk patients 
based on their platelet count at the time of hospitalization. 
The high-risk category patients should be given priority 
and the treating physician should take decision for platelet 
transfusion. Moderate risk patients should be observed 
carefully and platelet is transfused only if they have any 
haemorrhagic manifestations. Low risk patients should not 
be given any platelet transfusion and should be managed 
on intravenous fluids and supportive therapy.  
Makroo et al. [11] noted that many times the 
prescription for the platelet are not based on medical 
rationale, but as a response to an intense social pressure on 
the treating physicians by the patients and their relatives. 
Kumar et al. [13] also observed that the demands for 
platelet transfusion were mostly received as a panic 
reaction during the epidemic of dengue fever. Observing a 
fall in platelet count even if the count were above 20 × 
109/l, the blood prescribing clinicians had sent requisition 
for platelet transfusion without any specific indications. 
This actually led to non-availability of platelet in a centre 
not geared to meet excessive requirements of platelets. The 
same ‘chase’ for platelet counts has been mentioned by 
Ahluwalia [14]. The crux in treatment of dengue patients is 
maintenance of good hydration, monitoring for any over 
bleeding and not ‘panic’ if the platelet count is more than 
50,000/cumm. This ‘syndrome’ of chasing platelet count 
in dengue patients who are otherwise completely 
asymptomatic and improving can be labelled as ‘Dengue 
panic syndrome’. The efficacy of prophylactic platelet 
transfusion and the threshold for transfusion is 
questionable. Platelet transfusions are hardly ever required 
even with counts as low as 10,000/cumm because the 
circulating platelets are haematologically active and 
sufficient to prevent bleeding by thrombocytopenia per se 
(15). In general, platelet transfusions are given only when 
there are serious haemorrhagic manifestations. 
In our study, we have tried to show that the only trigger 
for the platelet transfusion is bleeding while platelet counts 
are not the trigger for platelet transfusion anymore. Many 
of the times it has been noticed that when platelet 
transfusion is given out of the fear and  patients receive 
multiple of transfusion since platelet takes almost around 
48 hours to stabilise, the patient is exposed to the risk of 
transfusion associated acute lung injury which increases 
significant morbidity, hospital stay and even rarely 
mortality. Also we have tried to show that there is no role 
of any antibiotics here while treating the dengue fever and 
misuse of antibiotics should be stopped to overcome the  
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very important problem of today that is antibiotic 
resistance. 
CONCLUSION 
Blood products are limited in developing countries and 
their use has to be justified. By doing close monitoring of 
symptoms, we can avoid most of the platelet transfusions 
in cases of dengue patients. This study highlights that 
platelet counts are not a trigger for the platelet transfusion 
even if the counts are less than 10000. Since our study 
only includes otherwise healthy young and middle aged 
adults so patient with co-morbidities may need to be very 
closely monitored for their symptoms specially bleeding.  
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